Pharma Update

Gazyva with best-in-disease potential in lupus nephritis Potential benefit in autoimmune diseases through sustained B cell depletion Gazyva (glycoengineered anti-CD20 mAb) Ph II (NOBILITY) results in LN1 Complete renal response Clinical trial program Type II anti-CD20 region 50% • Increased direct cell death Decreased CDC . Reduced internalization Indication Phl Ph II Ph III p<0.05 p<0.05 40% p<0.2 LN REGENCY 40% 41% 30% 35% MN MAJESTY 20% 23% 23% 18% Glycoengineered Fc region 10% SLE ALLEGORY • Higher FCYR affinity 0% Increased ADCC/ADCP Week 52 Week 76 Week 104 INS INShore Gazyva + MMF Placebo + MMF Roche · Greater potency than Rituxan in depleting • peripheral and tissue B-cells Ph II (NOBILITY) in LN met both primary and key secondary endpoints with no new safety signals; Placebo-corrected CRR of 22% at week 762,3 • Studies suggest that tissue based B-cells play a ⚫ Ph III (REGENCY) in LN fully recruited with results expected in 2024 major role in lupus nephritis • MN, SLE and INS: Complementary indications of the Gazyva program, with best-in-disease potential in MN, SLE and childhood onset INS 1. Furie R, et al. Ann Rheum Dis 2022; 81:100-107; 2.Furie R et al. Lupus Science & Medicine 2020;7 (Suppl 1):A27; 3.Furie R. et al; ACR 2019; mAb-monoclonal antibody; LN-lupus nephritis; MMF=mycophenolate mofetil; MN=membranous nephropathy; SLE-systemic lupus erythematosus; INS-Idiopathic nephrotic syndrome (Childhood onset INS also known as PNS-Pediatric nephrotic syndrome); CDC=complement-dependent cytotoxicity; ADCC-antibody-dependent cell-mediated cytotoxicity; ADCP-antibody-dependent cellular phagocytosis; CRR=complete renal response; IV-intravenous 114

View entire presentation